calendar
165 catalysts · 40 phase 2 completion · 25 phase 1 completion · 22 phase 1 2 completion · 20 phase 2 initiation · 17 phase 1 initiation · 12 phase 1 2 initiation
next 91 dayslessmore
MonWedFri
165 catalysts · 40 phase 2 completion · 25 phase 1 completion · 22 phase 1 2 completion · 20 phase 2 initiation · 17 phase 1 initiation · 12 phase 1 2 initiation
Therapy area: Cardiovascular, Oncology. Indication: Diffuse Large B-Cell Lymphoma, Hematological Tumor, Leukemia, Lymphoma, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Pulmonary Embolism, Thromboembolic Disease, Venous Thromboembolism
Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Triple-Negative Breast Cancer (TNBC)
Therapy area: Oncology. Indication: Mesenchymal Tumor
Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)
Therapy area: Oncology. Indication: Lung Cancer
Therapy area: Oncology. Indication: Endometrial Cancer
Therapy area: Oncology. Indication: Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma
Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders
Therapy area: Dermatology. Indication: Crow Feet, Unspecified Dermatological Disorders, Wrinkles, Xerosis (Dry Skin)
Therapy area: Oncology. Indication: Soft Tissue Sarcoma
Therapy area: Oncology. Indication: Neuroblastoma
Therapy area: Oncology. Indication: Prostate Cancer
Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer
Therapy area: Oncology. Indication: Colorectal Cancer
Therapy area: Oncology. Indication: Small-Cell Lung Cancer